2-Apr-2026
Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030
Globe Newswire (Tue, 24-Mar 4:57 PM ET)
Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth
Globe Newswire (Tue, 24-Mar 8:15 AM ET)
Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting
Globe Newswire (Wed, 18-Mar 7:00 AM ET)
Harrow’s TRIESENCE Pushes Forward: Phase 3 Trial Aims to Simplify Post-Cataract Care for Millions
Market Chameleon (Wed, 4-Mar 6:21 AM ET)
Harrow to Present at Leerink Partner's 2026 Global Healthcare Conference
Globe Newswire (Wed, 4-Mar 7:00 AM ET)
Globe Newswire (Tue, 3-Mar 7:00 AM ET)
Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance
Globe Newswire (Mon, 2-Mar 4:05 PM ET)
Globe Newswire (Wed, 18-Feb 7:00 AM ET)
Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack Kits
Globe Newswire (Tue, 17-Feb 7:00 AM ET)
OSRX Confirms Ongoing Licensing and Availability of Compounded Ophthalmic Medications in California
Business Wire (Tue, 3-Feb 5:00 AM ET)
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
Harrow trades on the NASDAQ stock market under the symbol HROW.
As of April 2, 2026, HROW stock price declined to $35.31 with 330,666 million shares trading.
HROW has a beta of 2.05, meaning it tends to be more sensitive to market movements. HROW has a correlation of 0.25 to the broad based SPY ETF.
HROW has a market cap of $1.31 billion. This is considered a Small Cap stock.
Last quarter Harrow reported $89 million in Revenue and $.17 earnings per share. This beat revenue expectation by $519,472 and missed earnings estimates by -$.28.
In the last 3 years, HROW traded as high as $59.23 and as low as $7.60.
The top ETF exchange traded funds that HROW belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
HROW has outperformed the market in the last year with a price return of +41.4% while the SPY ETF gained +18.2%. However, in the short term, HROW had mixed performance relative to the market. It has underperformed in the last 3 months, returning -27.9% vs -3.6% return in SPY. But in the last 2 weeks, HROW shares have fared better than the market returning +2.4% compared to SPY -0.6%.
HROW support price is $34.13 and resistance is $36.73 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HROW shares will trade within this expected range on the day.